Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2022-12-06 |
2022-09 |
-0.28 |
N/A |
N/A |
N/A |
2022-10-06 |
2022-06 |
-0.3 |
N/A |
N/A |
N/A |
2022-05-16 |
2022-03 |
-0.42 |
N/A |
N/A |
N/A |
2022-02-14 |
2021-12 |
-0.38 |
N/A |
N/A |
N/A |
2021-11-09 |
2021-09 |
-0.35 |
N/A |
N/A |
N/A |
2021-09-23 |
2021-06 |
-0.37 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2022-10-25 |
Wells Fargo |
Upgrade |
|
Equal-Weight |
2022-10-25 |
HC Wainwright & Co. |
Downgrade |
Buy |
Neutral |
2022-10-24 |
Wedbush |
Downgrade |
Outperform |
Neutral |
2022-10-24 |
Stifel |
Downgrade |
Buy |
Hold |
2022-10-04 |
Wells Fargo |
Downgrade |
Overweight |
Equal-Weight |
2022-09-30 |
Stifel |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2018-12-13 |
ALISKI WILLIAM E |
Director |
8.50K |
Purchase |
2019-07-10 |
FEINSOD MATTHEW |
Officer |
56.05K |
Stock Award(Grant) |
2019-05-27 |
KOENIG SCOTT |
Director |
34.25K |
Conversion of Exercise of derivative security |
2019-12-25 |
KROL PATRICK JOHAN HENDRIK |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
2022-06-30 |
POTTER STEPHEN W |
Officer |
55.88K |
Sale |
2022-08-18 |
REYNOLDS GERALD ANTHONY |
Officer |
51.01K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2022-09-29 |
Portolan Capital Management, LLC |
1.60M |
630.12K |
2.37% |
2022-09-29 |
Vanguard Group, Inc. (The) |
1.48M |
581.60K |
2.18% |
2022-09-29 |
Millennium Management Llc |
1.46M |
573.04K |
2.15% |
2022-09-29 |
Interwest Venture Management Co. |
1.40M |
552.82K |
2.08% |
2022-09-29 |
Kingdon Capital Management LLC |
1.23M |
482.16K |
1.81% |
2022-09-29 |
Renaissance Technologies, LLC |
1.14M |
447.72K |
1.68% |
Report Date |
Organization |
Position |
Value |
Percentage |
2022-06-29 |
Vanguard Total Stock Market Index Fund |
1.34M |
527.81K |
1.98% |
2022-08-30 |
Fidelity Strategic Advisors Small-Mid Cap Fund |
1.22M |
478.64K |
1.80% |
2022-06-29 |
Vanguard Extended Market Index Fund |
556.63K |
219.09K |
0.82% |
2022-09-29 |
Fidelity NASDAQ Composite Index ETF |
280.63K |
110.45K |
0.41% |
2022-08-30 |
Fidelity Extended Market Index Fund |
257.12K |
101.20K |
0.38% |
2022-09-29 |
iShares Micro Cap ETF |
115.23K |
45.35K |
0.17% |